These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8252498)

  • 41. Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).
    Decensi A; Guarneri D; Paoletti MC; Lalanne JM; Merlo F; Boccardo F
    Eur J Cancer; 1991; 27(9):1100-4. PubMed ID: 1835617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
    Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis of Deuterium Labeled 5, 5-Dimethyl-3-(α, α, α-trifluoro-4-nitro-m-tolyl) Hydantoin.
    Bolla RS; Gandikota NM; Kasi Viswanath IV
    Curr Radiopharm; 2019; 12(1):82-87. PubMed ID: 30854946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
    Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
    Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate.
    Pendyala L; Creaven PJ; Huben R; Tremblay D; Bertagna C
    Cancer Chemother Pharmacol; 1988; 22(1):69-76. PubMed ID: 3396147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Venner PM; Tewari HD
    Prog Clin Biol Res; 1987; 243A():391-400. PubMed ID: 3116550
    [No Abstract]   [Full Text] [Related]  

  • 47. [An unusual presentation of prostate cancer].
    Joual A; Rabii R; Aboutaeib R; el Moussaoui A; Benjelloun S
    Ann Urol (Paris); 1996; 30(5):262-3. PubMed ID: 8975593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maximal androgen blockade in prostatic cancer.
    Denis L
    Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
    [No Abstract]   [Full Text] [Related]  

  • 49. Anti-androgens in treatment of prostate cancer.
    Waxman J; Pandha H
    Lancet; 1995 Oct; 346(8981):1030. PubMed ID: 7475556
    [No Abstract]   [Full Text] [Related]  

  • 50. Anandron: a new step in the treatment of advanced prostate cancer. Proceedings of a symposium. June 12, 1989.
    Urology; 1991; 37(2 Suppl):1-32. PubMed ID: 1992597
    [No Abstract]   [Full Text] [Related]  

  • 51. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
    Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
    [No Abstract]   [Full Text] [Related]  

  • 52. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
    Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.
    Bennett CL; Raisch DW; Sartor O
    Ann Intern Med; 2002 Oct; 137(7):625. PubMed ID: 12353966
    [No Abstract]   [Full Text] [Related]  

  • 54. Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
    Pavone-Macaluso M; Cacciatore M; Daricello G; Pavone C; Serretta V
    Ann N Y Acad Sci; 1990; 595():328-33. PubMed ID: 2375611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug.
    Ask K; Dijols S; Giroud C; Casse L; Frapart YM; Sari MA; Kim KS; Stuehr DJ; Mansuy D; Camus P; Boucher JL
    Chem Res Toxicol; 2003 Dec; 16(12):1547-54. PubMed ID: 14680368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
    Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
    Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nilutamide pneumonitis: a report on eight patients.
    Pfitzenmeyer P; Foucher P; Piard F; Coudert B; Braud ML; Gabez P; Lacroix S; Mabille JP; Camus P
    Thorax; 1992 Aug; 47(8):622-7. PubMed ID: 1412120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiandrogen withdrawal syndrome with nilutamide.
    Gomella LG; Ismail M; Nathan FE
    J Urol; 1997 Apr; 157(4):1366. PubMed ID: 9120950
    [No Abstract]   [Full Text] [Related]  

  • 60. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
    Furr BJ
    Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.